AuthOr’s VIew AuthOr’s VIew

Dendritic cells (DCs) are central play-ers in the induction of adaptive immune responses. Upon infection or inflamma-tion, DCs take up antigens and migrate to lymphoid organs where they activate naïve antigen-specific T and B cells. This unique capacity of DCs is exploited worldwide for DC-based anticancer immunotherapy, a therapeutic approach aimed at eliciting specific antitumor immune responses.1 Thus far, the vacci-nation of cancer patients with DCs has proven to be feasible, safe and able to promote potent immune responses, pro-vided that DCs had been appropriatel